Physician profile
Fahd Rahman
NPI 1518165943
$1,427.31
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2021: $25.21 · 2022: $151 · 2023: $21.00 · 2024: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.38 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $210.52 | 2019-2024 | |
| Adc Therapeutics America, INC. | $125.00 | 2022 | |
| Daiichi Sankyo INC. | $113.81 | 2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $96.55 | 2019-2024 | Eliquis |
| Gilead Sciences, INC. | $95.95 | 2021-2024 | |
| Pfizer INC. | $84.43 | 2019-2024 | |
| Stemline Therapeutics INC. | $82.91 | 2019-2024 | Orserdu |
| Merck Sharp & Dohme LLC | $82.45 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $68.51 | 2024 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $54.99 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.58 | 2024 | Libtayo |
| Eisai INC. | $40.50 | 2024 | |
| Tesaro, INC. | $31.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.49 | 2019-2024 | |
| Abbvie INC. | $21.04 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Amgen INC. | $20.97 | 2019 | |
| Beigene USA, INC. | $20.43 | 2024 | Brukinsa |
| Janssen Pharmaceuticals, INC | $20.11 | 2019 | |
| Lilly USA, LLC | $19.48 | 2024 | Jaypirca |
| Emd Serono, INC. | $18.67 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.40 | 2019 | |
| Astellas Pharma US INC | $14.69 | 2024 | Padcev |
| Janssen Biotech, INC. | $14.16 | 2019 | |
| Celgene Corporation | $14.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2019 | |
| Partner Therapeutics, INC. | $13.82 | 2019 | |
| Incyte Corporation | $11.77 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahd Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.